Precision oncology
Read more
Combined biomarker analysis shows promise as a tissue agnostic response predictor for immunotherapy-based treatment
Pre-treatment expression of Ki-67 plus FOXC1 plus PD-L1 predicted response to neoadjuvant treatment in breast and head and neck tumours, although more work is required to determine its use in the context of immunotherapy alone
Lung and other thoracic tumours
Read more
Exploratory analysis of IMpower010 confirms that ctDNA is prognostic for adjuvant atezolizumab in NSCLC
However, improved outcomes are reported in PD-L1-positive patients only irrespective of post-operative and post-chemotherapy ctDNA status, calling into question its predictive value
Don't miss
-
Opening session
7 December 2022, 13:15-13:50, Room B -
Proffered paper session
7 December 2022, 14:05-15:40, Room B -
Mini Oral session
8 December 2022, 9:00-10:30, Room C
EDITORIAL
Back to basics: do we need more immuno-oncology in the core curriculum?
Due to the current widespread use of immunotherapies and their increasing complexities, further immune-oncology education is needed in medical schools and beyond
Congress Highlights
Preliminary activity is reported with an anti-IL-8 monoclonal antibody plus nivolumab in melanoma
Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors
Two studies explore new predictive biomarkers for immunotherapy in NSCLC
Different methods – multiparametric biomarker assessment and FDG-PET – show mixed accuracy and their applicability in clinical practice needs to be assessed
Do immune checkpoint inhibitors affect COVID-19 severity?
A joint analysis of the OnCovid and ESMO-CoCARE registries confirms the protective role of anti-SARS-CoV-2 vaccination in cancer patients treated with immunotherapy
Neoadjuvant camrelizumab plus chemotherapy improves pathologic complete response in stage IIIA and B NSCLC
Positive results from a phase II trial adds weight to the value of immunotherapy as neoadjuvant treatment for resectable NSCLC
Topics
Is there still a future for cancer vaccines?
Stephen P. Schoenberger
Is combining radiotherapy and immunotherapy a viable treatment option?
Jean-Pascal Machiels